References
[1] Block TM, Gish R, Guo H, et al. Chronic hepatitis B: what should be the goal for new therapies. Antiviral Res. 2013. 98(1): 27-34.
[2] Lok AS, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B cure: From discovery to regulatory approval. J Hepatol. 2017. 67(4): 847-861.
[3] Chu CM, Liaw YF. Prevalence of and risk factors for hepatitis B viremia after spontaneous hepatitis B surface antigen seroclearance in hepatitis B carriers. Clin Infect Dis. 2012. 54(1): 88-90.
[4] Lok AS, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B cure: From discovery to regulatory approval. Hepatology. 2017. 66(4): 1296-1313. 作者: TRUMPHILARY 时间: 2017-11-24 09:07